Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xinjie Hu
Observed name:
X. Hu
Institution:
Institute of Cancer Research
Observed institution:
Institute of Cancer Research
ORCID:
0009-0000-1545-7191
Observed ORCID:
0009-0000-1545-7191
OpenAlex ID:
A5137858693
Expansion cohorts in phase 1 oncology trials: a systematic review of their design, implementation and outcomes
2026
·
Julio Herrero Colomina
, Xinjie Hu
, et al.
·
British Journal of Cancer
·
4
PDF
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
·
Clinical Cancer Research
·
3
DOSET: dose optimization with simultaneous efficacy and toxicity evaluation, motivated by a first-in-human phase I CAR T lymphoma trial
2026
·
X. Hu
, R. Benjamin
, et al.
·
ESMO Open
·
1
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 5 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplemental Tables 1-2 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Show more works
View as search
Works count:
12
Citation count:
8
H-index:
2
I10-index:
Year
Topic
Type